DTIL

Precision BioSciencesB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$14.00

+90.2% vs current

Most likely

Base case

45%

Probability

Target price

$8.00

+8.7% vs current

B-

Bear case

25%

Probability

Target price

$3.50

-52.4% vs current

AI sentiment snapshot

Latest data as of 2026-06-18

AI commentary

Primary-source tone since early May has been constructive, centered on pipeline execution, runway, and conference-driven HBV updates, with the June 16 loan amendment adding a modest balance-sheet positive. But coverage remains thin, no sufficient social-context packet is available, and no clear analyst-revision wave is in evidence, so sentiment still looks event-driven and best framed as a cautious monitoring-style speculative long rather than a broadly validated consensus story.

RankAlpha Sentiment Codex - 2026-06-18

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystRunway support and debt-maturity extension ease near-term financing pressureHigh impact

Precision said on May 5 that cash, cash equivalents and restricted cash were $125.8 million at March 31, 2026 and should fund data milestones for PBGENE-HBV and PBGENE-DMD through 2028, while the June 16 8-K said Banc of California amended the loan agreement to extend term-loan maturity to December 31, 2029 [#SEC-8K-2026-05-05] [#8-K-2026-06-16].

2026-09-30eventAdditional PBGENE-HBV clinical updates remain the main near-term trading driverHigh impact

The May 5 company 8-K said PBGENE-HBV had treated 16 patients with 38 administrations across five cohorts and that Precision expects further clinical data at hepatitis-focused medical conferences during 2026, after highlighting a late-breaking EASL poster on cccDNA elimination and inactivation [#SEC-8K-2026-05-05].

2026-12-31catalystPBGENE-DMD enrollment and first patient data are the next platform-validation legHigh impact

Precision said PBGENE-DMD received FDA IND clearance and Fast Track designation, activated its first clinical site, is enrolling patients, and expects data from multiple patients by year-end 2026, making execution in FUNCTION-DMD the next major platform milestone after HBV updates [#SEC-8K-2026-03-12] [#SEC-8K-2026-05-05].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-18 • Updated nightlySource: Internal modelMethodology